Trial Profile
A Phase 1 First-in-Human Dose Study of LY3023414 in Patients With Advanced Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Samotolisib (Primary) ; Abemaciclib; Cisplatin; Fulvestrant; Letrozole; Midazolam; Pemetrexed
- Indications Advanced breast cancer; B-cell lymphoma; Cancer; Lymphoma; Malignant-mesothelioma; Mesothelioma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; First in man
- Sponsors Eli Lilly and Company
- 07 Apr 2022 Status changed from active, no longer recruiting to completed.
- 05 Jan 2022 Planned End Date changed from 1 Oct 2021 to 31 Jan 2022.
- 05 Aug 2021 Planned End Date changed from 1 Mar 2021 to 1 Oct 2021.